

Investor Update

Welcome to the first edition of Medibio Limited's Investor Update newsletter. The quarterly newsletter will provide Medibio Limited investors with a snapshot of the company's activities, upcoming milestones and developments.

Dear Shareholders,

It is with great pleasure that I welcome you to the first edition of Medibio's Investor Update newsletter.

2015 is set to be an exciting year for the company, with our Circadian Heart Rate (CHR) technology for the diagnosis of depression and other mental health disorders on track to progress through a number of key milestones on its path to commercialisation.

In December, we entered into an agreement with the Johns Hopkins School of Medicine to undertake a U.S.-based independent clinical validation study of our CHR technology. Johns Hopkins is a \$7 billion integrated global health enterprise and one of the leading health care organisations in the United States, with over 124 years' experience in ground-breaking research, teaching, and medical services. The study is expected to be completed within 12 months. We have also appointed NAMSA, a leading US-based Regulatory Advisory and Clinical Research organisation, to assist with trial design and regulatory discussions with the U.S. Food and Drug Administration (FDA).

In Sydney, we will shortly be commencing our Australian independent clinical validation study with the Black Dog Institute, Australia's pre-eminent mental health research organisation and a world leader in the diagnosis, treatment and prevention of depression, bipolar disorder and suicide. We are expecting results from the Black Dog Institute's Australian clinical validation study in Q4 2015.

We recently announced results from a comprehensive commercialisation study on our CHR depression test

technology, undertaken by the Ametus Group in Minnesota, USA. This study confirmed the commercial potential of Medibio's technology and its applications in US markets. In the coming quarter, investors can expect to see a number of exciting developments relating to new strategic partnerships, ongoing product development, and early revenue opportunities relating to the rollout of the corporate stress-test and mental wellbeing products.


We are confident that our CHR diagnostic technology is a game-changer and believe that it is well-positioned to become the first FDA approved, quantitative/evidence based test for depression and anxiety. Depression is estimated to cost the U.S. economy US\$83 billion a year, with the cost in Australia estimated at \$15 billion annually, representing a great opportunity for early movers in the space.

2015 will be an important year for our company, which I look forward to sharing with all of you. I would like to thank all of the shareholders for their ongoing support and belief in our strategy and look forward to sharing the forthcoming exciting developments with you over the next few months.

Regards,

Kris Knauer
Director





A revolutionary mental health diagnostic test

- Our CHR technology has the potential to be the world's first FDA approved diagnostic test for mental illness and depression.
- This patented innovative unique technology is non intrusive, quick, objective, decisive, and will revolutionise the diagnosis and treatment of mental health.
- Over 10 years of research into the relationship between the autonomic nervous system, psychological state and heart rate activity.
- First revenue from the roll out of a corporate stress and wellbeing product is anticipated this year.

[Click here to learn more about Medibio's CHR technology.](#)

Mental health in Australia

A significant cost burden

According to the Australian Institute of Health and Welfare's report, *Australia's Health 2014*, there is a high prevalence of mental disorders within the Australian population. During the ages of 16–85, around 7.3 million, or 45% of Australians will experience a common mental health-related condition such as depression, anxiety or a substance use disorder.

When examining what contributes most to the burden of disease in Australasia, AIHW identified mental and behavioural disorders as contributing to 13% of the total burden, exceeded only by cancer (16%), musculoskeletal disorders (15%) and cardiovascular diseases (14%). Mental and behavioural disorders also accounted for 23% of the non-fatal burden in 2010.

There are 16 million mental health related GP visits annually in Australia. *Australia's Health 2014* also highlighted depression as being one of the most common chronic conditions managed by GPs in 2012–13, accounting for 7.3% of all chronic conditions. Depression was also ranked as the fourth largest burden of disease in 2010. Mental health, was cited as the third most costly disease group in 2008–09 at \$6.38 billion or 8.6% of total allocated health expenditure.

[To access the full Australian Institute of Health & Welfare report, click here.](#)

Key company milestones

Q1 2015

- Initiate discussions with the U.S. FDA
- Initiate U.S. and Australian validation studies
- Confirm strategic partner for portable device

Q2 2015

- Complete development of Corporate Stress product
- Commercial launch of Corporate Stress product

Q3 2015

- Commercial partnership with U.S. strategic partner

Q4 2015

- Results from U.S. and Australian validation studies
- Submission to FDA

Target markets

Widespread applications throughout:

MEDICAL

- Primary Care Physicians
- Psychiatrists
- Psychologists
- Therapists
- Counsellors

CORPORATE

- High risk occupations
- Insurance Companies
- Corporate Screening
- Professions
- Elite Sports

CONSUMER

- Direct Consumer
- Ideal for wearables

Articles of Interest

The Herald Sun - [Sad fact is that drugs can't cure everything](#)

ABC News - [OECD snapshot ranks Australia second in world in anti-depressant prescriptions](#)

Sydney Morning Herald - [How my brief patch of insomnia saw me labelled with depression](#)

Companies & Markets - [Antidepressants market growing in the US with drugs also used to treat sleep problems and anxiety disorders](#)

The Independent - [Anti-depressant prescriptions in Britain have doubled in past 10 years](#)



Recent company Announcements

Johns Hopkins University School of Medicine to Undertake US-based Clinical Validation Study on Medibio's Depression Test

Sydney, Australia – 1 December 2014: Medibio Ltd announced that it has entered into an agreement with The Johns Hopkins University School of Medicine (JHM), located in Baltimore, Maryland, USA, to undertake a US-based independent clinical validation study of the Company's Circadian Heart Rate ("CHR") Technology to assist clinicians in the diagnosis of depression.

[Click here to view the full ASX announcement.](#)

Medibio appoints US-based CRO for its validation trials

Sydney, Australia – 5 December 2014: Medibio Ltd announced that it has appointed NAMSA, a respected US-based regulatory advisory and clinical research organization to coordinate its recently announced US clinical study to ensure that the Company's depression validation study meets FDA regulatory requirements.

[Click here to view the full ASX announcement.](#)

Investor Presentation

Sydney, Australia - 23 January 2015: Medibio Ltd released an investor presentation detailing the company's 2015 plans and commercialisation strategy.

[Click here to view the presentation.](#)

Update on corporate reorganisation

Sydney, Australia – 29 January 2015: Medibio Ltd announced that it has entered into various legal documents with the shareholders of Invatec Pty Limited ("Invatec"), the entity which is the owner of the new diagnostic test for depression and other mental health disorders technology which will result in 100% ownership by the Company.

[Click here to view the full ASX announcement.](#)

Notice of General Meeting, Explanatory Memorandum and Independent Expert's Report

Sydney, Australia – 3 February 2015 - Medibio Ltd General Meeting to be held on Friday 6th March, 10:30am. C/- PKF Lawler Level 8, No.1 O'Connell Street Sydney NSW 2000.

[Click here to view the full ASX announcement.](#)

Commercialisation study confirms a \$2 billion revenue opportunity for the US medical market relating specifically to depression

Sydney, Australia – 6 February 2015: Medibio Ltd released details of a comprehensive commercialisation study on its CHR depression test technology for the US Market.

[Click here to view the full ASX announcement.](#)



Current Directors:

Vincent John Fayad
Kris Knauer
James Campbell

Current Company Secretary:
Robert Lees

Registered Office:

c/- CoySec Services, Suite 605, Level 6
50 Clarence Street Sydney NSW 2000

Share Registry:

Computershare Investor Services
Pty Limited
Level 117 Victoria Street
West End QLD 4101
Tel: 1300 787 272

Auditors:

William Buck (Qld)
Level 21, 307 Queen Street
Brisbane QLD 4000

Australian Legal Advisors:

Thomson Geer
Level 25, 1 O'Connell Street
SYDNEY NSW 2000

Independent Expert:

Grant Thornton Corporate Finance
Pty Limited
AFSL: 247140
Level 17, 383 Kent Street
Sydney NSW 2000